Skip to content
Drug Development with Dr Clifton Barry episode artwork

Dec 31, 2023 42 min

Drug Development with Dr Clifton Barry

from The TBPod Hosted by Actnet

Today we speak with Dr Clifton Barry from NIH in Bethesda, Maryland who is head of the most highly cited research group in the field of TB over the past year and has made extraordinary contributions to TB drug development. Dr Barry speaks about his involvement in the PREDICT TB study, the TB Drug Accelerator and some of the most exciting drug developments in recent years. REFERENCES Green, Simon R., et al. "Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs." Nature communications 13.1 (2022): 5992. https://predict-tb.com/ Lange, Christoph, Clifton E. Barry III, and C. Robert Horsburgh Jr. "Treatments of multidrug-resistant tuberculosis: light at the end of the tunnel." American Journal of Respiratory and Critical Care Medicine 205.10 (2022): 1142-1144. Khan, RM Naseer, et al. "Distributable, metabolic PET reporting of tuberculosis." bioRxiv (2023). Cole, STea, et al. "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence." Nature 396.6707 (1998): 190-190. Finin, Peter, et al. "Chemical approaches to unraveling the biology of mycobacteria." Cell Chemical Biology 30.5 (2023): 420-435. Libardo, M. Daben J., et al. "Resistance of Mycobacterium tuberculosis to indole 4-carboxamides occurs through alterations in drug metabolism and tryptophan biosynthesis." Cell Chemical Biology 28.8 (2021): 1180-1191. Barry, Clifton E., Helena IM Boshoff, and Cynthia S. Dowd. "Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis." Current pharmaceutical design 10.26 (2004): 3239-3262. Xie, Yingda L., et al. "Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis." Science Translational Medicine 13.579 (2021): eabd7618.

Episode details come from the podcast's RSS feed.

Embed this episode

Today we speak with Dr Clifton Barry from NIH in Bethesda, Maryland who is head of the most highly cited research group in the field of TB over the past year and has made extraordinary contributions to TB drug development. Dr Barry speaks about his involvement in the PREDICT TB study, the TB Drug Accelerator and some of the most exciting drug developments in recent years. REFERENCES Green, Simon R., et al. "Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs." Nature co...

Ready to play

Drug Development with Dr Clifton Barry

0:00 42:02

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The TBPod?

This episode is 42 minutes long.

When was this The TBPod episode published?

This episode was published on December 31, 2023.

Can I download this The TBPod episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.